Teropavimab and zinlirvimab sensitivity in people living with multidrug-resistant HIV-1: data from the PRESTIGIO Registry.

ABSTRACT: We characterized sensitivity to teropavimab (TAB) and zinlirvimab (ZAB) in people living with four-class drug-resistant HIV (4DR-PWH). This was a multicenter, observational study using plasma or peripheral blood mononuclear cells collected from 50 4DR-PWH (25 with HIV-1 RNA > 1,000 copies/mL matched by age, sex, nadir CD4+, and years on ART to 25 virologically suppressed [HIV-1 RNA < 50 copies/mL]) enrolled in the PRESTIGIO Registry (NCT04098315) with a documented 4DR (NRTIs, NNRTIs, PIs, and INSTIs). Phenotypic sensitivity to bNAbs was determined using the PhenoSense monoclonal antibody assay (Monogram), with susceptibility defined as IC₉₀ ≤ 2 µg/mL. The HIV-1 envelope was genotyped by next-generation sequencing, and sequences were analyzed for the presence of multi-position HI

SUBMITTER: Spagnuolo V 

PROVIDER: S-EPMC12502735 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature